Arbor Day Foundation: 30% of Tree Projects Related to Extreme Heat in 2024
'Communities are struggling to endure the pressures of rising heat and they're reaching for trees as a way to cope. This data is a validator of trees in their role as critical infrastructure. In our world's cities, trees are a 'must-have', not just a 'nice-to-have',' said Dan Lambe, chief executive of the Arbor Day Foundation. 'As the rate of extreme heat increases, so must our response. The Arbor Day Foundation is focused on leveraging the latest data and technology to help reach communities in need. Alongside our global network of planting partners, we're meeting the moment with action.'
The new data analysis from the Arbor Day Foundation revealed last year's 115 heat-related projects resulted in more than 52,000 trees planted or distributed with the specific aim of creating cooling. These trees were brought into front yards, back yards, city streets, parks, playgrounds, and school campuses across 27 U.S. states and seven additional countries.
Trees planted in cities and neighborhoods have the power to reduce life-threatening heat by up to 10 degrees Fahrenheit and improve air quality worsened by the heat.
According to the World Meteorological Organization, the last 10 years have been the hottest years on the planet, with 2024 being the hottest ever recorded. The rising heat has proven deadly. The National Weather Service estimates extreme heat accounts for more deaths annually in the U.S. than every other natural disaster combined. Additionally, extreme heat is proven to increase hospitalizations related to cardiovascular and respiratory illnesses.
In total in 2024, the Arbor Day Foundation planted or distributed a combined 1.5 million trees across 409 tree planting projects in cities and towns. In addition to extreme heat, projects helped to improve air quality, support disaster recovery efforts, establish food forests, and grow green spaces in undercanopied areas. The work was accomplished in collaboration with 235 local planting partners in 46 U.S. states and 28 countries.
Click here to learn more about how the Arbor Day Foundation leverages data, science and mapping to focus its work in communities where extreme heat has a disproportionate impact.
About the Arbor Day Foundation
The Arbor Day Foundation is a global nonprofit inspiring people to plant, nurture, and celebrate trees. They foster a growing community of more than 1 million leaders, innovators, planters, and supporters united by their bold belief that a more hopeful future can be shaped through the power of trees. For more than 50 years, they've answered critical need with action, planting more than half a billion trees alongside their partners.
And this is only the beginning.
The Arbor Day Foundation is a 501(c)(3) nonprofit pursuing a future where all life flourishes through the power of trees. Learn more at arborday.org.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
6 hours ago
- Newsweek
Millions Across 11 States Told To Stay out of Sun, Limit Activity
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of Americans across almost a dozen states were instructed to stay out of the sun and limit outdoor activities, as the National Weather Service (NWS) issued a sweeping series of extreme heat warnings and advisories amid dangerous temperatures. Dozens of cities in 11 states throughout the South, Midwest, and Southwest face dangerous heat, prompting health alerts and safety guidance for vulnerable communities. Why It Matters The Centers for Disease Control and Prevention (CDC) warned that extreme heat is the deadliest weather phenomenon in the United States, causing more than 700 deaths annually. Vulnerable populations, including children, seniors, and people with chronic health conditions, face elevated risks of heat-related illness such as heat stroke and exhaustion. Rising temperatures also amplify ground-level ozone pollution, compounding risks for those with asthma or heart complaints. People drink water as they walk along the National Mall near the Washington Monument in Washington, D.C., on July 25, 2025, as a heat dome sits over the region leading to extremely high temperatures. People drink water as they walk along the National Mall near the Washington Monument in Washington, D.C., on July 25, 2025, as a heat dome sits over the region leading to extremely high temperatures. Getty Images What To Know According to the NWS Extreme Heat Warning map and recent reports, extreme heat warnings are in effect for 11 states—affecting hundreds of cities and millions of residents. The hardest-hit areas were parts of Iowa, southwest Minnesota, northeast Nebraska, and most of South Dakota. These regions are forecast to experience heat index values at or above 110 degrees Fahrenheit. In their statements on the heat warning, the NWS advised: "Drink plenty of fluids, stay in an air-conditioned room, stay out of the sun, and check up on relatives and neighbors." Officials reiterated not to leave children or pets unattended in vehicles, as car interiors can reach deadly temperatures within minutes. "For the Heat Advisory, warm and muggy conditions will continue early this morning. For the Extreme Heat Warning, dangerously hot conditions with heat index values 111 to 115 expected," the NWS said. Simultaneously, less severe heat advisories stretched across the South, Midwest, and Northeast—including Georgia and southeast South Carolina, where forecast heat index values routinely top 100 F. Cities across affected regions have opened cooling centers for residents without air conditioning, with officials encouraging people to stay indoors and avoid outdoor activities during peak heat hours. The exact temperature thresholds that trigger heat advisories vary geographically, but all current warnings indicate conditions that push the human body beyond normal heat tolerance limits. What People Are Saying The NWS in Phoenix, Arizona, said in a statement on Sunday: "Drink plenty of fluids, stay in an air-conditioned room, stay in the shade, and check up on relatives and neighbors. "Do not leave young children and pets in unattended vehicles. Car interiors will reach lethal temperatures in a matter of minutes. "Take extra precautions when outside. Wear lightweight and loose fitting clothing. Try to limit strenuous activities to early morning or evening. Take action when you see symptoms of heat exhaustion and heat stroke." What Happens Next At the time of publication, the latest extreme heat warnings remain in effect until at least 9 p.m. CDT Thursday, with the NWS advising residents to stay informed as conditions may shift.
Yahoo
a day ago
- Yahoo
Why is it so hot? If you live in a city, the answer might surprise you.
PHILADELPHIA ‒ It was another brutally hot day in a summer that has seen more than its share of them. Temperatures were in the high 80s, but with the oppressive humidity, heat indices reached into the low 100-degree range. And in Hunting Park, a working-class neighborhood in North Philadelphia, it felt even hotter. Heat radiated in waves off concrete sidewalks and asphalt streets. Garage owners left their bay doors open and residents sat on the front stoops and porches of their row houses, hoping to get a little relief from even more sweltering temperatures inside. "There's a lot of asphalt and cement," said Jemile Tellez Lieberman, who works in research, health equity and community engagement for Esperanza, a neighborhood nonprofit. All that pavement, along with a constant flow of cars, densely packed housing, and a lack of greenery, means Hunting Park is warmer than leafier pockets of the city ‒ an urban heat island where temperatures can be as much as 7 degrees higher than the rest of the city during the day. There are pockets like this all over Philadelphia, and in cities all over the country. One solution, say a growing number of researchers and urban advocates, is trees. "If you plant a tree, this will benefit your neighborhood in 5, 10, 50 years," said Lauren Marshall, director of landscape restoration for the Arbor Day Foundation, a nonprofit dedicated to planting trees. Dangerous heat, disproportionate impact Adding trees doesn't just make a neighborhood look better. It makes it healthier, too, Marshall said. "Heat kills more people than any other natural phenomenon in the United States," she said. "So trees will be more important than ever, especially in urban areas." Visualizing the issue: Yes, it's hotter in the city. See how the urban heat island effect works. In 2023, more Americans died from heat-related causes than in any year since 1999, when tracking began. More than 2,300 people died from heat that year, the study, from the American Medical Association study found. But those researchers believe that was likely an undercount. Children, the elderly and people with preexisting health conditions are the most vulnerable to high temperatures. And low-income communities are more likely to swelter in heat islands, research by the U.S. Environmental Protection Agency and others has shown. A study by Climate Central found that 41 million Americans live in census tracts across 44 cities with an urban heat island index of 8 degrees or higher. New York (9.5 degrees), San Francisco (8.8), Chicago and Miami (8.3) and Seattle (8.2) are among the U.S. cities with the highest urban heat island indices. The effect can differ among cities. Some, including Albuquerque, Indianapolis, Las Vegas, Philadelphia, Sacramento, San Antonio and Tulsa, have higher temperatures concentrated within an urban core. Other cities including Atlanta, Denver, Baltimore, Boston, Chicago and Milwaukee, have more diffused areas of heat intensity, with smaller differences in temperature between their urban core and their outlying areas. How trees can help people, and how people can help trees Like a lot of urban neighborhoods across the United States, Hunting Park faces a wide range of challenges, from poverty to underfunded schools. So prioritizing tree-planting can be a tough sell, Esperanza's Tellez Lieberman said. Esperanza, which supports the Latino community in Hunting Park, has found that engagement is key, she said. "We let (residents and business owners) take the lead in discussions about what trees they want and where to plant them." It also takes a lot of trees to make a difference. A 2019 study found that a neighborhood has to be at least 40% covered by trees ‒ counting pavement and buildings ‒ to substantially limit heat. That amount of tree coverage can reduce temperatures by seven to nine degrees, according to the University of Wisconsin researchers. Esperanza works with the Arbor Day Foundation, Pennsylvania Horticultural Society, Tree Philly and the city's Department of Parks and Recreation to plant trees every the spring and fall. The trees are provided at no cost to residents, and they are planted in places where they can grow and flourish. "Trees need maintenance," Tellez Lieberman noted. "They can tangle with wires or their roots can upend pipes, and it can be cost-prohibitive to get one removed, so we work with people to pair the right tree with the right person for support and maintenance." The Arbor Day Foundation uses data, including GIS (geographic information systems) mapping, its GIS director Derrick Frese explained, to help determine which areas should be prioritized because they have too little greenery, denser populations and higher temperatures. They're beginning to examine the benefits of trees in a more data-focused way as well, Frese said. "Now we can capture a ton of information, like how much water runoff is captured, how many trees are planted, how many people are impacted." But the benefits can go beyond a bit of shade and a little green in a gray cityscape, said Marshall of the Arbor Day Foundation. "What I love about trees is that they are part of the solution to so many problems," she said. "Improving air quality, mitigating water runoff. They can even bring in some food, like fruit, draw in more wildlife, and we've even heard it brings more people to walk around." This article originally appeared on USA TODAY: Why is it so hot? Cities swelter when trees disappear. Solve the daily Crossword
Business Wire
2 days ago
- Business Wire
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.
